The Point Where HS Calls for a Biologic

When does hidradenitis actually call for a biologic?

When the disease is moderate to severe and antibiotic-based therapy has not controlled it. In practice that means recurring inflamed lesions across more than one body area, sinus tracts or scarring already present, and flares frequent enough that a person is rarely out of one. Hurley staging forms part of how that severity is assessed at the visit 1Ref 1Alikhan A, Sayed C, Alavi A, et al. (2019).North American clinical management guidelines for hidradenitis suppurativa: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.That severity assessment in hidradenitis, including Hurley staging, is part of diagnosis and evaluation; and that procedural management such as deroofing and wider surgical approaches remains part of care for structurally damaged areas alongside medical therapy., and the structural findings it captures carry the most weight in the decision.

Two things are worth stating plainly. First, the threshold is not a waiting period. Nothing is earned by working through more antibiotic courses once it is clear they are not holding. Second, the threshold moves with impact: someone with fewer lesions in an anatomically punishing location, unable to sit through a shift or to work at all, can reasonably cross it sooner than a lesion count alone would suggest.

Diagnostic delay complicates the picture. HS diagnostic delay runs to years for most people, which means many arrive at a dermatology office already meeting the criteria for systemic therapy at their very first visit 2Ref 2Sabat R, Jemec GBE, Matusiak Ł, et al. (2020).Hidradenitis suppurativa.The long diagnostic delay characteristic of hidradenitis; the progression from inflammatory nodules to sinus tracts and permanent scarring; and the management sequence from topical antiseptic and antibiotic therapy through systemic antibiotic combinations before systemic immunomodulating treatment.. Being told at a first appointment that a biologic is appropriate is not a sign that things are moving too fast. Usually it means they moved far too slowly for a long time beforehand.

What moderate-to-severe means in hidradenitis

It is a composite judgment rather than a single number: how many inflamed lesions there are, how many separate regions are involved, whether sinus tracts and scarring have formed, and how much pain and drainage the disease produces day to day. Severity assessment at diagnosis takes in all of these together 1Ref 1Alikhan A, Sayed C, Alavi A, et al. (2019).North American clinical management guidelines for hidradenitis suppurativa: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.That severity assessment in hidradenitis, including Hurley staging, is part of diagnosis and evaluation; and that procedural management such as deroofing and wider surgical approaches remains part of care for structurally damaged areas alongside medical therapy., which is why two people with similar-looking skin can land on different sides of the line.

The structural findings. Sinus tracts — the tunnels that connect recurring lesions beneath the surface — and the rope-like scarring that follows them mark the transition out of the earliest stage of disease 2Ref 2Sabat R, Jemec GBE, Matusiak Ł, et al. (2020).Hidradenitis suppurativa.The long diagnostic delay characteristic of hidradenitis; the progression from inflammatory nodules to sinus tracts and permanent scarring; and the management sequence from topical antiseptic and antibiotic therapy through systemic antibiotic combinations before systemic immunomodulating treatment.. Their presence changes the conversation permanently, because they do not resolve with medication.

The areas involved. Disease in one armpit is a different proposition from disease in both armpits, the groin, and under the breasts. Multiple regions is among the strongest practical arguments for systemic treatment.

The part no scale captures. Drainage that requires dressings and a change of clothes at work. Pain that makes sitting impossible. The social cost of odor and staining, and the withdrawal that follows it. Clinicians who treat HS regularly weight this heavily, and describing it accurately at an appointment is information, not complaint.

The trial that made adalimumab the first biologic for HS

Two phase 3 randomized, placebo-controlled trials — PIONEER I and PIONEER II — tested adalimumab on a weekly schedule in adults with moderate-to-severe hidradenitis suppurativa and found significantly higher clinical response at week 12 than placebo. That result is the basis for the first biologic indication in HS 3Ref 3Kimball AB, Okun MM, Williams DA, et al. (2016).Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.That PIONEER I and PIONEER II, two phase 3 randomized placebo-controlled trials, showed weekly adalimumab significantly increased clinical response at week 12 in moderate-to-severe hidradenitis suppurativa, forming the basis for the first biologic indication in HS., and it is the reason this drug is usually the first one discussed.

What response meant. A meaningful reduction in inflammatory lesions without an increase in abscesses or draining tunnels. It is an improvement measure, not disappearance of the disease. Reading that honestly matters: a substantial share of participants improved and a substantial share did not, and no biologic in HS is a switch that turns the condition off.

Why it changed the field anyway. Before these trials, hidradenitis had no systemic therapy tested at that level of rigor, and treatment rested on antibiotics and surgery in whatever combination a clinician favored. A randomized result gave dermatologists something to point at, insurers something to approve, and patients a known probability rather than a hope.

A biologic in HS is judged by whether flares become fewer and less severe, not by whether the skin becomes normal.

What comes before it, and what waiting costs

Before a biologic, most people will have worked through topical antiseptic washes and topical antibiotic therapy — clindamycin for HS is the usual topical — and then one or more of the antibiotic combinations that quiet HS for a stretch 2Ref 2Sabat R, Jemec GBE, Matusiak Ł, et al. (2020).Hidradenitis suppurativa.The long diagnostic delay characteristic of hidradenitis; the progression from inflammatory nodules to sinus tracts and permanent scarring; and the management sequence from topical antiseptic and antibiotic therapy through systemic antibiotic combinations before systemic immunomodulating treatment.. Those steps are legitimate and they carry a great many people for a long time. The real question is what happens when they stop being enough.

The cost of an open-ended trial-and-error phase. Inflammation that persists builds tunnels and scar tissue, and that architecture is permanent 2Ref 2Sabat R, Jemec GBE, Matusiak Ł, et al. (2020).Hidradenitis suppurativa.The long diagnostic delay characteristic of hidradenitis; the progression from inflammatory nodules to sinus tracts and permanent scarring; and the management sequence from topical antiseptic and antibiotic therapy through systemic antibiotic combinations before systemic immunomodulating treatment.. Every month spent cycling through another antibiotic course in disease that is visibly progressing is a month in which reversible inflammation can convert into irreversible structure.

What that does not mean. It does not mean jumping straight to a biologic is right for everyone, and it does not mean antibiotic therapy is wasted effort. It means the review point matters. A plan should have a date on which someone asks whether this is actually working, rather than drifting from refill to refill for two years.

Arriving at that review with dated photographs and a rough flare diary changes what it produces. Memory reliably undersells a disease that has slowly become normal.

What starting a biologic involves

A short workup, then injections at home. The screening and monitoring that accompany biologic therapy are best documented in psoriasis, where these drugs have been used longest: the AAD-NPF guideline sets out the pre-treatment screening, including latent tuberculosis, and the ongoing monitoring expected for each biologic class 4Ref 4American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.The pre-treatment screening — including latent tuberculosis screening — and the ongoing safety monitoring established for biologic classes in psoriasis, cited here as the best-documented example of the workup that accompanies biologic therapy in dermatology.. The same practical apparatus surrounds a biologic prescribed anywhere in dermatology.

The rhythm. Subcutaneous injection with a prefilled pen, done at home after a short teaching session. Specialty-pharmacy delivery, refrigeration, and a sharps container become unremarkable parts of the week faster than most people expect.

Infection sense. The one rule worth holding is to call rather than guess when a significant fever arrives, and to report a persistent cough or drenching night sweats promptly rather than saving them for the next scheduled visit.

What does not change. Wound care, dressings, and pain management continue alongside. A biologic reduces new inflammation; it does not close a tunnel that already exists, and procedural options remain part of the plan for areas that are already structurally damaged 1Ref 1Alikhan A, Sayed C, Alavi A, et al. (2019).North American clinical management guidelines for hidradenitis suppurativa: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.That severity assessment in hidradenitis, including Hurley staging, is part of diagnosis and evaluation; and that procedural management such as deroofing and wider surgical approaches remains part of care for structurally damaged areas alongside medical therapy..

How other skin conditions set the same threshold

Dermatology repeats this pattern across conditions: topical therapy first, systemic therapy when disease is extensive or when topical treatment has failed, and a randomized trial that fixes where the line sits. Recognizing the pattern elsewhere makes the hidradenitis version less alarming and easier to argue for.

In atopic dermatitis, the SOLO 1 and SOLO 2 trials tested dupilumab in adults with moderate-to-severe disease inadequately controlled by topical therapy, and it improved signs, symptoms, itch, and quality of life 5Ref 5Simpson EL, Bieber T, Guttman-Yassky E, et al. (2016).Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.That the SOLO 1 and SOLO 2 phase 3 trials studied dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical therapy and showed improvement in signs, symptoms, itch, and quality of life — used as a parallel example of an escalation threshold defined by severity plus topical failure.. The entry criterion is the threshold made explicit: extensive disease that topicals did not hold.

In alopecia areata, the BRAVE-AA1 and BRAVE-AA2 trials tested oral baricitinib in adults with severe disease and found significantly greater hair regrowth than placebo 6Ref 6King B, Ohyama M, Kwon O, et al. (2022).Two Phase 3 Trials of Baricitinib for Alopecia Areata.That the BRAVE-AA1 and BRAVE-AA2 phase 3 trials showed oral baricitinib superior to placebo for hair regrowth in adults with severe alopecia areata — used as a parallel example of a systemic-treatment threshold defined by disease extent.. That is a systemic alopecia threshold set by extent of involvement rather than by how long someone has endured it.

The shared structure is worth naming: severity, plus failure of the tier below, plus a trial population that defines who the evidence actually speaks for. HS is not an exception to how dermatology escalates. It is simply the condition where the delay before escalation has historically been longest.

What to ask if the first biologic does not hold

Ask three questions, and ask them at a scheduled review rather than in the middle of a flare. Whether the response is genuinely inadequate or whether too little time has passed to judge it. Whether anything modifiable is working against the drug — tobacco, untreated metabolic disease, or an area that needs procedural attention rather than more medicine. And what the next option would be.

That last question has more answers than it did a decade ago. Different cytokines are now being targeted in this disease, and the newer biologics reaching for HS act through pathways other than TNF. Whether one of them fits a particular person is a conversation for the dermatologist who knows the case; it is not something an article can settle from a description.

What stays on the table throughout. Procedures. Deroofing and wider surgical approaches to a damaged area are not an admission that medication failed — combined medical and procedural management is standard practice in established disease 1Ref 1Alikhan A, Sayed C, Alavi A, et al. (2019).North American clinical management guidelines for hidradenitis suppurativa: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.That severity assessment in hidradenitis, including Hurley staging, is part of diagnosis and evaluation; and that procedural management such as deroofing and wider surgical approaches remains part of care for structurally damaged areas alongside medical therapy..

Needing a second or third agent is ordinary in hidradenitis and is not a sign the situation is hopeless. Most durable HS plans are built by iteration rather than chosen correctly the first time.